title: [In vitro activity of the echinocandins. How should it be evaluated?].
abstract: Echinocandins are a novel class of antifungal drugs. They have good activity against Candida spp and Aspergillus spp. Their low selective toxicity allows their administration at high doses with few secondary side effects. We have reviewed the available data on the endpoints for these drugs in their in vitro susceptibility testing on yeasts and moulds. The microdilution broth method is the most commonly used technique and MIC-1 (80% of growth inhibition) seems to be the most reliable endpoint when yeasts are tested. This endpoint also seems to be the most appropriate for the different drugs when they are combined with echinocandins using the checkerboard method for testing yeasts. By contrast, in the case of moulds, the minimum effective concentration (MEC) correlates better with the in vivo activity than the MIC when echinocandins are tested, and when these drugs are combined with other antifungals, MIC-2 (50% of growth inhibition) seems the most appropriate endpoint. Criteria based on drug pharmacodynamics is the most useful to define the echinocandin endpoints that best correlate with their in vivo efficacy.
authors.affiliation: Unitat de Microbiologia, Facultat de Medicina i Ciencies de la Salut, Universitat Rovira i Virgili, Reus, Spain. franciscojavier.pastor@urv.es
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Pastor
authors.forename: Josep
authors.initials: J
authors.lastname: Guarro
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology*; D001230:Aspergillus / Q000187:drug effects; D004341:Drug Evaluation / Q000379:methods*; D005656:Fungal Proteins / Q000494:pharmacology*; D005658:Fungi / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods*; D010456:Peptides, Cyclic / Q000494:pharmacology*; D015003:Yeasts / Q000187:drug effects
chemical_list: D000935:Antifungal Agents; D005656:Fungal Proteins; D010456:Peptides, Cyclic